Eli Lilly and Company (LLY)vsNeurocrine Biosciences Inc (NBIX)
LLY
Eli Lilly and Company
$1,131.42
-2.41%
HEALTHCARE · Cap: $948.95B
NBIX
Neurocrine Biosciences Inc
$163.88
-2.07%
HEALTHCARE · Cap: $16.06B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 2229% more annual revenue ($72.25B vs $3.10B). LLY leads profitability with a 35.0% profit margin vs 21.5%. NBIX appears more attractively valued with a PEG of 0.45. NBIX earns a higher WallStSmart Score of 81/100 (A-).
LLY
Strong Buy78
out of 100
Grade: B+
NBIX
Exceptional Buy81
out of 100
Grade: A-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Growing faster than its price suggests
Revenue surging 42.2% year-over-year
Earnings expanding 2311.0% YoY
Safe zone — low bankruptcy risk
Keeps 22 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : NBIX
The strongest argument for NBIX centers on PEG Ratio, Revenue Growth, EPS Growth. Profitability is solid with margins at 21.5% and operating margin at 22.8%. Revenue growth of 42.2% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Bear Case : NBIX
The primary concerns for NBIX are Piotroski F-Score.
Key Dynamics to Monitor
LLY carries more volatility with a beta of 0.48 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NBIX scores higher overall (81/100 vs 78/100), backed by strong 21.5% margins and 42.2% revenue growth. Both earn "Exceptional Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Neurocrine Biosciences Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric diseases and disorders in the United States. The company is headquartered in San Diego, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?